Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCIA vs 3+7 Induction in Newly Diagnosed High-Risk AML (Young Adults)
ChiCTR2500109161Phase 4Recruiting
- Sponsor
- Medical Center of Hematology, Xinqiao Hospital, Army Medical University
- Start
- Sep 2025
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of cyclophosphamide, PD-1 Monoclonal Antibody, idarubicin and cytarabine in acute myeloid leukemia (AML) (2 arms), sponsored by Medical Center of Hematology, Xinqiao Hospital, Army Medical University. Primary endpoint: Remission rate of induction therapy. Started Sep 2025; status: recruiting.
02
Drugs
cyclophosphamidePD-1 Monoclonal Antibodyidarubicincytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2500109161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109161.